Diode laser transscleral cyclophotocoagulation followed by phacotrabeculectomy on medically unresponsive acute primary angle closure eyes: the long-term result by unknown
Liu et al. BMC Ophthalmology 2014, 14:26
http://www.biomedcentral.com/1471-2415/14/26RESEARCH ARTICLE Open AccessDiode laser transscleral cyclophotocoagulation
followed by phacotrabeculectomy on medically
unresponsive acute primary angle closure eyes:
the long-term result
Wei Liu, Yanhui Chen, Yingjuan Lv, Linni Wang, Xiaoli Xing, Aihua Liu and Jian Ji*Abstract
Background: To explore the intraocular pressure-lowering effect and complications of diode laser transscleral
cyclophotocoagulation (DLTSC) followed by phacotrabeculectomy on medically unresponsive acute primary
angle closure eyes.
Methods: Nine eyes of nine medically unresponsive acute primary angle closure patients were enrolled. All the
patients underwent cyclophotocoagulation followed by phacotrabeculectomy to control the prolonged acute
attack. Data were recorded prospectively and then analyzed retrospectively. The reduction in intraocular
pressure, improvement of vision and the complications were evaluated.
Results: After DLTSC, the IOP of all the patients were reduced, but all were above 21 mmHg under topical
anti-glaucoma medications. After phacotrabeculectomy, the IOP of all the patients was decreased. At the final
visit, the vision of all the patients was improved and the IOP of all the patients was below 21 mmHg without
anti-glaucoma medications. There were no complications during the DLTSC and phacotrabeculectomy. Uveitis
was the common complications after the both procedures, which were resolved by medication treatment.
Conclusion: Diode laser transscleral cyclophotocoagulation followed by phacotrabeculectomy is an alternative
procedure to control the intraocular pressure of medically unresponsive acute primary angle closure eyes with
few complications.
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Acute primary angle closure (APAC) is a common oph-
thalmic emergency that requires early treatment. The
longer the duration of increased intraocular pressure
(IOP), the more irreversible damage there is to the optic
nerve head, iris, lens, endothelium, and drainage path-
ways [1,2]. Early aggressive management of an acute epi-
sode is crucial to prevent development of primary angle
closure glaucoma (PACG) after APAC and to relieve the
excruciating symptoms of the patients [3].
The conventional treatment for APAC is to reduce
IOP medically, after which laser peripheral iridoplasty or* Correspondence: tjykzx@aliyun.com
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unless otherwise stated.iridotomy (LPI) is performed. However, in some eyes,
the acute attack is severe and often refractory to medical
treatment [4-7], and the prolonged poor cornea clarity of
APAC patients limits the application of LPI. In such cases,
trabeculectomy is occasionally performed as an urgent
intervention [6]. However, for medically unresponsive
APAC cases, trabeculectomy on inflamed ‘hot’ eyes with
high IOP poses a high risk of surgical failure and complica-
tions, such as suprachoroidal hemorrhage [4,8-10].
Is there any other method to control the high IOP of
medically unresponsive APAC eyes? Diode laser trans-
scleral cyclophotocoagulation (DLTSC), initially reserved
for eyes with refractory glaucoma and limited visual
prognosis, is now being used more widely, even as pri-
mary surgical treatment in glaucoma therapy, includingThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[7,11], chronic angle closure glaucoma [12,13], and
even eyes with good vision [14]. In this study, we aimed
to explore the safety and efficacy of DLTSC followed
by phacotrabeculectomy on Chinese medically unre-
sponsive APAC eyes.Methods
Patients
Consecutive medically unresponsive APAC patients ac-
cepted DLTSC followed by phacotrabeculectomy from
November 2008 to October 2010 were included in this
study. Data were recorded prospectively and then analyzed
retrospectively. This study adheres to the Declaration of
Helsinki and was approved by the ethics committee of
Tianjin Medical University Eye Hospital. Informed consent
was obtained from each patient.
All the patients underwent a thorough ocular examin-
ation, including visual acuity, slit-lamp biomicroscopy,
IOP, B-scan, ultrasound biomicroscopy etc at presenta-
tion. Post-operative evaluation was conducted on days 1,
7 and months 1, 3, 6 and 12. The patients, who needed
closer follow-up, according to the clinical outcome, were
evaluated monthly or even weekly. On each occasion,
the patients were fully examined under the slit-lamp
biomicroscopy. The visual acuity and IOP were deter-
mined. Any complications of surgery were noted. All the
IOP was measured by non-contact tonometer (Full Auto
Tonometer TX-F, Canon, Japan) for three times and the
average was recorded.Diode laser transscleral cyclophotocoagulation
Diode laser transscleral cyclophotocoagulation was per-
formed with the OcuLight SLx 810 nm diode laser photo-
coagulator and the handheld fiberoptic G-probe, both from
Iris Medical Instruments (Mountain View, CA) [13,15]. All
the treatments were performed under local anesthesia
(2 ml of 2% lidocaine as a retrobulbar injection). The laser
was set at an initial power of 1700 mW and a duration of
1 second. The laser power was titrated upwards and down-
wards during the procedure. The target was to achieve a
‘burst’ sound in roughly half of the laser applications. Laser
applications were spaced evenly over the inferior 180
degrees, while sparing the 3- and 9-o’clock regions.
Post-operatively, all preoperative IOP-lowering medica-
tions, except systemic medications (such as high-osmotic
agents) and topical pilocarpine, were continued. The pa-
tients were also given tobramycin and dexamethasone
eye drops (TobraDex, S.A. Alcon-Couvreur N.V., Rijksweg,
Puurs, Belgium) 6 times per day, 1% atropine gel (Dishan,
Xingqi Co., Ltd, Shenyang, China) twice per day, and pra-
noprofen eye drops (Pranopulin, Senju Pharmaceutical Co.,
Ltd, Osaka, Japan) 4 times per day.Phacotrabeculectomy
All the surgeries were performed by the same experienced
surgeon (JJ). During the surgery, after the fornix-based con-
junctival flap and rectangular scleral flap were performed,
mitomycin-C (MMC) was applied under the conjunctival
and scleral flaps. Then, the phacoemulsification and intra-
ocular lens (IOL) implantation was performed, followed by
trabeculectomy and peripheral iridectomy. The scleral flap
and the conjunctival wound were closed with 10/0 nylon
sutures at the end of the surgery.
After surgery, all IOP-lowering medications were discon-
tinued. Postoperative medications employed routinely are
tobramycin and dexamethasone eye drops (TobraDex, S.A.
Alcon-Couvreur N.V., Rijksweg, Puurs, Belgium) 6 times
per day, and pranoprofen eye drops (Pranopulin, Senju
Pharmaceutical Co., Ltd, Osaka, Japan) 4 times per day. All
the drops were discontinued after 6 weeks of treatment.
Results
Patients’ characteristics
Nine consecutive medically unresponsive APAC patients
(9 eyes) were enrolled in this study. All of the patients
presented with symptoms of eye pain, blurred vision,
headache and nausea. The duration of the acute attack
ranged from 6 days to 23 days. The vision of the patients
was threatened mostly by significant cornea edema. The
IOP of the patients ranged from 43.2 mmHg to 58.7 mmHg,
despite maximum medication. None of the patients were
performed laser peripheral iridotomy for corneal edema.
The detailed patient characteristics are indicated in Table 1.
Clinical outcome after DLTSC
There were no complications during the DLTSC procedure.
After DLTSC, the IOP of all the patients was lower, but all
were above 21 mmHg (from 23.3 to 32 mmHg) under top-
ical anti-glaucoma medications. After DLTSC, corneal
edema of all the patients was relieved in part. All the pa-
tients experienced uveitis (aqueous flare: from ++ to +++),
5 patients experienced subconjunctival hemorrhage, and
only 1 patient experienced exudation in the anterior cham-
ber, indicating a relatively severe inflammatory reaction.
Clinical outcome after phacotrabeculectomy
After phacotrabeculectomy, the IOP of all the patients
was lower. The follow-up period ranged from 14 months
to 35 months. At the final visit, the vision of all the pa-
tients was improved and the IOP of all the patients was
below 21 mmHg (from 12.8 to 18 mmHg) without anti-
glaucoma medications or other surgical interventions.
The detailed IOP results are indicated in Table 2.
There were no complications during the surgery. At
1 day after surgery, all the patients presented with cor-
nea edema and uveitis and 3 patients presented with
exudation in the anterior chamber, which were resolved









1 Left 7 1% pilocarpine QID, 2% carteolol Q12H, 0.2% Brimonidine BID 43.2 HM
2 Left 11 1% pilocarpine Q2H, 1% Brinzolamide TID, 0.2% Brimonidine BID, oral Methazolamide
25 mg BID, intravenous 20% mannitol 250 ml QD
43.6 1.0
3 Right 7 1% pilocarpine QID, 2% carteolol Q12H, 0.2% Brimonidine BID, intravenous 20%
mannitol 400 ml QD
45.0 2.0
4 Left 6 1% pilocarpine QID, 2% carteolol Q12H, 1% Brinzolamide TID, oral Methazolamide
50 mg BID, intravenous 20% mannitol 400 ml Q12H
48.6 0.9
5 Right 23 1% pilocarpine QID, 2% carteolol Q12H, 1% Brinzolamide TID, oral Methazolamide
25 mg BID, intravenous 20% mannitol 250 ml Q12H
54.2 HM
6 Left 20 1% pilocarpine TID, 2% carteolol Q12H, 1% Brinzolamide TID, 0.2% Brimonidine BID,
oral Methazolamide 50 mg BID
58.7 HM
7 Left 15 1% pilocarpine QID, 2% carteolol Q12H, 1% Brinzolamide TID, 0.2% Brimonidine BID,
oral Methazolamide 25 mg BID
44.8 FC
8 Right 17 1% pilocarpine QID, 1% Brinzolamide TID, 0.2% Brimonidine BID, oral Methazolamide
25 mg BID, intravenous 20% mannitol 250 ml QD
47.0 1.0
9 Right 12 1% pilocarpine QID, 2% carteolol Q12H, 1% Brinzolamide TID, 0.2% Brimonidine BID,
oral Methazolamide 25 mg BID, intravenous 20% mannitol 400 ml QD
50.0 FC
IOP: intraocular pressure, VA: vision acuity, HM: hand movement, FC: finger counting.
Case 1, 6 and 7 were not administered mannitol for systemic disease (such as renal dysfunction, cardiac insufficiency, etc), case 2 and 8 were not administered
beta-blocker for atrioventricular block, case 1 and 3 were not administered carbonic anhydrase inhibitors for medication allergy.
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or combined with YAG laser (1 patient). No other com-
plications were encountered during the follow-up after
the surgery.
Discussion
To date, many methods have been studied to control the
IOP of APAC. The conventional initial treatment may
involve one or more of the IOP-lowering drugs. How-
ever, for a significant proportion of APAC patients, these
treatments may fail to reduce IOP. [1] Laser peripheralTable 2 Clinical outcome after DLTSC and phacotrabeculectom
Case 1
Total laser energy (J) 68
IOP 1 day after laser (mmHg) 27.8
Days between procedures (depending on the corneal clarity and
inflammation)
3
MMC (mg/ml, min) 0.2, 1.5
IOP before surgery (mmHg) 23.9
IOP 1 day after surgery (mmHg) 11.6
IOP 1 week after surgery (mmHg) 17.1
IOP 1 month after surgery (mmHg) 8.7
IOP 6 months after surgery (mmHg) 10.2
IOP 1 year after surgery (mmHg) 11.2
Final IOP (mmHg) (months from presentation) 13.4
(22)
Final VA (LogMAR) 0.7
DLTSC: diode laser transscleral cyclophotocoagulation, IOP: intraocular pressure, MMiridotomy appears to be effective and safe in controlling
rising IOP [16-19]. However, for Asian eyes, the results
after LPI are not satisfactory [20,21]. Moreover, the appli-
cation of LPI is compromised by the edematous cornea of
APAC patients. In cases when LPI is not possible, immedi-
ate paracentesis has been proposed as an alternative pro-
cedure to rapidly lower the IOP [22]. However, the
performance of paracentesis in an eye with APAC has
many unique technical difficulties [1], and the paracentesis
itself runs the risk of ocular decompression retinopathy
[23] and intraocular inflammation. Therefore, in selectedy
2 3 4 5 6 7 8 9
100 68 90 110 76 82 90 86
23.3 30.0 29.5 31.1 28.4 25.9 32.0 27.7
8 2 3 5 7 10 4 7
0.2, 1.0 0.2, 2.0 0.3, 2.0 0.2, 2.0 0.2, 3.0 0.2, 2.0 0.3, 2.0 0.2, 2.0
22.0 28.0 31.0 28.7 32.0 29.7 26.6 25.7
19.6 8.6 21.7 15.8 22.0 14.6 18.7 23.0
11.0 10.0 20.4 17.4 15.9 13.9 14.8 9.0
13.5 14.8 9.5 14.3 16.1 14.1 13.3 10.5
12.8 13.9 14.7 15.6 14.4 10.7 16.1 9.5

















1.0 0.5 0.4 0.3 0.5 0.2 0.2 0.3
C: mitomycin-C, VA: vision acuity.
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as a primary procedure to lower the IOP [6]. However, for
medically unresponsive cases of APAC, trabeculectomy
on eyes with high IOP has a high risk of surgical failure
and complications, especially suprachoroidal hemorrhage
[4]. As a severely debilitating complication of glaucoma
surgery, suprachoroidal hemorrhage has been reported to
be strongly associated with the level of the preoperative
IOP in several studies [8-10].
Diode laser transscleral cyclophotocoagulation, trad-
itionally used only in eyes with advanced end stage
glaucoma and with little or no visual potential, has
now become a popular minimally invasive treatment
for glaucoma [7,11-14]. The 810 nm diode wavelength
is twice as efficient for DLTSC than the Nd:YAG wave-
length of 1064 nm, and the near infrared light gener-
ated by the diode laser is absorbed better by melanin
than the longer wavelengths [14,24]. This advantage
allows the diode laser to use less energy to produce
comparable lesions.
In this study, for medically unresponsive APAC eyes,
firstly, we tried DLTSC to control the high IOP. Although
the IOP was decreased after DLTSC, the desired degree of
reduction was not achieved. The authors think this is
mostly because of the conservative protocol for DLTSC in
our study, or APAC is not sensitive to DLTSC, which needs
further study to confirm. In order to avoid severe complica-
tion, we adopted the narrow laser scope (only the inferior
180 degrees), a short laser duration time (1000 ms) and low
laser energy (1700 mW) during the DLTSC. The only
article covering the use of DLTSC on APAC eyes in the lit-
erature included 5 APAC cases from two ophthalmic units
in the United Kingdom [25]. All of their 5 cases achieved
successful control of IOP and resolution of the acute attack
after DLTSC, which is different from the results in our case
series. The mechanism of their better control of IOP was
not clear; we think it may be partly due to the iridotomy or
iridoplasty performed before DLTSC in most of their cases.
Although the IOP was not controlled under 21 mmHg
after DLTSC, the cornea edema was relieved and the
IOP was decreased in part, which enabled us to perform
phacotrabeculectomy with a lower risk of severe compli-
cations. After the surgery, the IOP of all the eyes was
controlled to an ideal level and visual acuity was signifi-
cantly improved. Moreover, except for uveitis and cornea
edema, no other severe complications (such as vision
loss, phthisis and suprachoroidal hemorrhage, etc.) were
encountered after DLTSC and filtration surgery. One
reason might be the comparatively low laser energies we
applied in comparison with other investigators, who
treated with 1.75–3 W for 2 s [26-29]. Another might be
the relieved corneal edema and the decreased IOP by
DLTSC before phacotrabeculectomy, which simplified
the surgical manipulations.The authors acknowledge the limitations of the
study. This was a non-comparative case series and
the sample size was relatively small. The laser energy
employed and the MMC protocol used were not uni-
form and the IOP-lowering effect of cataract surgery
alone was not evaluated. A prospective comparative
study (filtration surgery after DLTSC versus filtration
surgery under high IOP) with larger samples would be
ideal. Further study to compare the IOP-lowering
effect of different DLTSC protocols on APAC eyes is
needed. However, in this study, the authors did, indeed,
propose an alternative procedure to control the IOP of
medically unresponsive APAC eyes without severe
complications.
Conclusions
Diode laser transscleral cyclophotocoagulation followed by
phacotrabeculectomy is an alternative procedure to control
the intraocular pressure of medically unresponsive acute
primary angle closure eyes with few complications.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JJ and XX designed and supervised the study; LW drafted the manuscript; CY
and WL collected the data; LY and LA analyzed the data and helped to draft
the manuscript. All authors read and approved the final manuscript.
Acknowledgements
We thank Dr Jun Qiao who helped to collect the data and Dr Tian Tian who
helped to proofread the manuscript.
Received: 23 October 2013 Accepted: 4 March 2014
Published: 10 March 2014
References
1. Lam DS, Tham CC, Lai JS, Leung DY: Current approaches to the
management of acute primary angle closure. Curr Opin Ophthalmol 2007,
18:146–151.
2. David R, Tessler Z, Yassur Y: Long-term outcome of primary acute
angle-closure glaucoma. Br J Ophthalmol 1985, 69:261–262.
3. Tan AM, Loon SC, Chew PT: Outcomes following acute primary angle closure
in an Asian population. Clin Experiment Ophthalmol 2009, 37:467–472.
4. Aung T, Tow SL, Yap EY, Chan SP, Seah SK: Trabeculectomy for acute
primary angle closure. Ophthalmology 2000, 107:1298–1302.
5. Seah SK, Foster PJ, Chew PT, Jap A, Oen F, Fam HB, Lim AS: Incidence of
acute primary angle-closure glaucoma in Singapore. An island-wide
survey. Arch Ophthalmol 1997, 115:1436–1440.
6. Buckley SA, Reeves B, Burdon M, Moorman C, Wheatcroft S, Edelsten C,
Benjamin L: Acute angle closure glaucoma: relative failure of YAG
iridotomy in affected eyes and factors influencing outcome. Br J
Ophthalmol 1994, 78:529–533.
7. Kramp K, Vick HP, Guthoff R: Transscleral diode laser contact
cyclophotocoagulation in the treatment of different glaucomas, also as
primary surgery. Graefes Arch Clin Exp Ophthalmol 2002, 240:698–703.
8. Speaker MG, Guerriero PN, Met JA, Coad CT, Berger A, Marmor M: A
case-control study of risk factors for intraoperative suprachoroidal
expulsive hemorrhage. Ophthalmology 1991, 98:202–209. discussion 210.
9. Jiraskova N, Rozsival P, Pozlerova J, Ludvikova M, Burova M: Expulsive
hemorrhage after glaucoma filtering surgery. Biomed Pap Med Fac Univ
Palacky Olomouc Czech Repub 2009, 153:221–224.
10. The Fluorouracil Filtering Surgery Study Group: Risk factors for
suprachoroidal hemorrhage after filtering surgery. Am J Ophthalmol 1992,
113:501–507.
Liu et al. BMC Ophthalmology 2014, 14:26 Page 5 of 5
http://www.biomedcentral.com/1471-2415/14/2611. Grueb M, Rohrbach JM, Bartz-Schmidt KU, Schlote T: Transscleral diode
laser cyclophotocoagulation as primary and secondary surgical treatment in
primary open-angle and pseudoexfoliatve glaucoma. Long-term clinical
outcomes. Graefes Arch Clin Exp Ophthalmol 2006, 244:1293–1299.
12. Lai JS, Tham CC, Chan JC, Lam DS: Diode laser transscleral
cyclophotocoagulation in the treatment of chronic angle-closure
glaucoma: a preliminary study. J Glaucoma 2003, 12:360–364.
13. Lai JS, Tham CC, Chan JC, Lam DS: Diode laser transscleral
cyclophotocoagulation as primary surgical treatment for medically
uncontrolled chronic angle closure glaucoma: long-term clinical
outcomes. J Glaucoma 2005, 14:114–119.
14. Ansari E, Gandhewar J: Long-term efficacy and visual acuity following
transscleral diode laser photocoagulation in cases of refractory and
non-refractory glaucoma. Eye (Lond) 2007, 21:936–940.
15. Pokroy R, Greenwald Y, Pollack A, Bukelman A, Zalish M: Visual loss after
transscleral diode laser cyclophotocoagulation for primary open-angle
and neovascular glaucoma. Ophthalmic Surg Lasers Imaging 2008,
39:22–29.
16. Lai JS, Tham CC, Chua JK, Lam DS: Immediate diode laser peripheral
iridoplasty as treatment of acute attack of primary angle closure
glaucoma: a preliminary study. J Glaucoma 2001, 10:89–94.
17. Lai JS, Tham CC, Chua JK, Poon AS, Chan JC, Lam SW, Lam DS: To compare
argon laser peripheral iridoplasty (ALPI) against systemic medications in
treatment of acute primary angle-closure: mid-term results. Eye (Lond)
2006, 20:309–314.
18. Lam DS, Lai JS, Tham CC, Chua JK, Poon AS: Argon laser peripheral
iridoplasty versus conventional systemic medical therapy in treatment of
acute primary angle-closure glaucoma: a prospective, randomized,
controlled trial. Ophthalmology 2002, 109:1591–1596.
19. Saunders DC: Acute closed-angle glaucoma and Nd-YAG laser iridotomy.
Br J Ophthalmol 1990, 74:523–525.
20. Aung T, Ang LP, Chan SP, Chew PT: Acute primary angle-closure: long-term
intraocular pressure outcome in Asian eyes. Am J Ophthalmol 2001, 131:7–12.
21. Lai JS, Tham CC, Chua JK, Poon AS, Lam DS: Laser peripheral iridoplasty as
initial treatment of acute attack of primary angle-closure: a long-term
follow-up study. J Glaucoma 2002, 11:484–487.
22. Lam DS, Chua JK, Tham CC, Lai JS: Efficacy and safety of immediate anterior
chamber paracentesis in the treatment of acute primary angle-closure
glaucoma: a pilot study. Ophthalmology 2002, 109:64–70.
23. Rao SK, Greenberg PB, Macintyre RB, Ducharme JF: Ocular decompression
retinopathy after anterior chamber paracentesis for uveitic glaucoma.
Retina 2009, 29:280–281.
24. Lin P, Wollstein G, Glavas IP, Schuman JS: Contact transscleral neodymium:
yttrium-aluminum-garnet laser cyclophotocoagulation Long-term outcome.
Ophthalmology 2004, 111:2137–2143.
25. Manna A, Foster P, Papadopoulos M, Nolan W: Cyclodiode laser in the
treatment of acute angle closure. Eye (Lond) 2012, 26:742–745.
26. Brancato R, Carassa RG, Bettin P, Fiori M, Trabucchi G: Contact transscleral
cyclophotocoagulation with diode laser in refractory glaucoma. Eur J
Ophthalmol 1995, 5:32–39.
27. Rebolleda G, Munoz FJ, Murube J: Audible pops during cyclodiode
procedures. J Glaucoma 1999, 8:177–183.
28. Schlote T, Derse M, Rassmann K, Nicaeus T, Dietz K, Thiel HJ: Efficacy and
safety of contact transscleral diode laser cyclophotocoagulation for
advanced glaucoma. J Glaucoma 2001, 10:294–301.
29. Threlkeld AB, Johnson MH: Contact transscleral diode
cyclophotocoagulation for refractory glaucoma. J Glaucoma 1999, 8:3–7.
doi:10.1186/1471-2415-14-26
Cite this article as: Liu et al.: Diode laser transscleral
cyclophotocoagulation followed by phacotrabeculectomy on medically
unresponsive acute primary angle closure eyes: the long-term result.
BMC Ophthalmology 2014 14:26.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
